News

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

Kyowa Kirin expands the license agreement with one new ADC…

eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine

A year after the establishment of the mRNA Vaccine Technology…

Versameb to Present during World Continence Week 2022

Lead therapeutic candidate has the potential to treat Stress…

Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases

Nordic Bioscience, a growing biomarker company, today announced…

Biocomposites appoints Group Chief Financial Officer and New UK General Manager

Keele, UK, 15 June 2022 – Biocomposites, an international…

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1…

Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)

PKA pension fund lead investment, alongside The Danish Growth…

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study

Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc.,…

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Oversubscribed financing co-led by HealthCap and EQT Life Sciences…

Bionical Solutions Bolsters Clinical Services Team

Willington, UK, 7 June 2022 – Bionical Solutions, a leading…

Verona Pharma to Host KOL Event on June 16, 2022

LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona…

Destiny Pharma plc – Result of Annual General Meeting and Strategy Update

Brighton, United Kingdom - 27 May 2022 - Destiny Pharma plc…

Destiny Pharma appoints three Non-Executive Directors

Brighton, United Kingdom - 26 May 2022 - Destiny Pharma plc…

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge.

ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community

Los Angeles, USA and Yantai, China – May 24th, 2022 - ImaginAb,…

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.